CLINICAL OBSERVATIONS OF L-CARNITINE COMBINED WITH HEMODIALYSIS FOR THE TREATMENT OF UREMIC PERIPHERAL NEUROPATHY

YUNQIAN WANG, HUICONG LI, BAOPING CHEN

Department of Nephrology, Henan University Huaihe Hospital, Kaifeng 475000, China

This paper aimed to explore and analyze the clinical therapeutic effect of L-carnitine combined with hemodialysis for the treat- ment of uremic peripheral neuropathy. 5000 cases of uremic peripheral neuropathy patients admitted to our hospital were selected, and were divided into experimental and control groups based on their different treatment programs. 2500 cases of uremic peripheral neuropathy patients in the control group were treated with conventional hemodialysis therapy, while 2,500 patients in the experimen- tal group were treated with L-carnitine combined with hemodialysis. The purpose of the controlled trial was to compare the clinical outcomes of the two groups. Statistical analysis of the differences in clinical treatment outcome between the two groups was perfor- med with Chi-square and t tests.

Results: showed that there were varying degrees of improvement in various clinical indicators after the treatment. Clinical symptom improvement, improvement in nerve conduction velocity, and the overall treatment effectiveness in the experimental group patients treated with L-carnitine combined with hemodialysis were significantly superior to those of the control group patients treated simply with hemodialysis. Differences between the groups were statistically significant (p <0.05). Based on the experimental fin- dings, it can be concluded that treatment of uremic peripheral neuropathy patients with L-carnitine combined with hemodialysis yiel- ded significant and reliable clinical effects. It can effectively speed up nerve conduction velocity with clinical significance, and is thus worthy of increased use in clinical practice.